CAR T cells plus acalabrutinib for mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether modified immune cells (CD19 CAR T cells) given with the medicine acalabrutinib can help people with mantle cell lymphoma that has come back or did not respond. It may help by attacking lymphoma cells more strongly and improving disease control after prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign consent to join the study
- You have CD19-positive mantle cell lymphoma confirmed from a prior biopsy (or current biopsy if needed)
- You must currently be taking acalabrutinib for about 3–7 months, and your lymphoma is still measurable or active
- Your health tests are within safe limits (blood counts, liver/kidney function, and heart strength)
- You can safely have a treatment procedure to collect cells (leukapheresis) and receive related medicines
- You do not have certain recent or high-risk medical problems (like recent transplants or uncontrolled infections)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a targeted pill (nemtabrutinib) to standard CAR T-cell therapy for people with mantle cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination works better than CAR T alone.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This trial studies acalabrutinib given after certain lymphoma treatments (like stem cell transplant or CAR T therapy) to help keep the lymphoma from coming back. It’s for people whose disease has shrunk (partial response) or fully gone away (complete response) after those treatments.
This trial tests a combination of two targeted drugs (acalabrutinib and rituximab) for people with mantle cell lymphoma who have not had treatment before. It is designed for older patients or younger patients with a less aggressive form of the disease.
This trial tests adding acalabrutinib (a targeted therapy) to standard chemotherapy (R-CHOP) for people with mantle cell lymphoma who have not had treatment before and cannot have a stem cell transplant. The goal is to see if the combination works better than R-CHOP alone.
This trial tests if adding the targeted therapy pirtobrutinib before CAR T-cell treatment (Tecartus) works better for mantle cell lymphoma that has come back or not responded to other treatments. It aims to improve outcomes for patients who are eligible for CAR T-cell therapy.
Hear when a new Recurrent Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.